ATE313562T1 - Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins - Google Patents

Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins

Info

Publication number
ATE313562T1
ATE313562T1 AT00981916T AT00981916T ATE313562T1 AT E313562 T1 ATE313562 T1 AT E313562T1 AT 00981916 T AT00981916 T AT 00981916T AT 00981916 T AT00981916 T AT 00981916T AT E313562 T1 ATE313562 T1 AT E313562T1
Authority
AT
Austria
Prior art keywords
human lactoferrin
antimicrobial effect
polypeptides
cluster
cationic
Prior art date
Application number
AT00981916T
Other languages
English (en)
Inventor
Berkel Patrick Hendrikus C Van
Peter Hendrikus Nibbering
Jan Henricus Nuijens
Original Assignee
Am Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am Pharma Bv filed Critical Am Pharma Bv
Application granted granted Critical
Publication of ATE313562T1 publication Critical patent/ATE313562T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT00981916T 1999-11-11 2000-11-10 Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins ATE313562T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16497599P 1999-11-11 1999-11-11
EP99203775 1999-11-11
PCT/NL2000/000821 WO2001034641A2 (en) 1999-11-11 2000-11-10 Antimicrobial activity of the first cationic cluster of human lactoferrin

Publications (1)

Publication Number Publication Date
ATE313562T1 true ATE313562T1 (de) 2006-01-15

Family

ID=26153390

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981916T ATE313562T1 (de) 1999-11-11 2000-11-10 Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins

Country Status (11)

Country Link
EP (1) EP1228097B1 (de)
JP (1) JP2003521483A (de)
AT (1) ATE313562T1 (de)
AU (1) AU776044B2 (de)
CA (1) CA2388910C (de)
CY (1) CY1105008T1 (de)
DE (1) DE60025026T2 (de)
DK (1) DK1228097T3 (de)
ES (1) ES2256070T3 (de)
PT (1) PT1228097E (de)
WO (1) WO2001034641A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072322A2 (en) * 2000-03-27 2001-10-04 Pharming Intellectual Property B.V. High dosage parenteral administration of lactoferrin
EP1414866A2 (de) * 2000-11-21 2004-05-06 The Texas A & M University System Fgf-affinitätschromatographie
EP1360961A1 (de) * 2002-05-07 2003-11-12 AM-Pharma B.V. Verwendung von antimikrobiell wirkenden Peptiden zur Aktivitätssteigerung von antimikrobiellen Wirkstoffen
JP2007536201A (ja) * 2003-07-16 2007-12-13 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 宿主防御因子ｘ（ｈｄｆｘ）
WO2007055578A1 (en) * 2005-11-11 2007-05-18 Leids Universitair Medisch Centrum Cyclic antimicrobial peptides derived from lactoferrin
JP5322108B2 (ja) * 2006-07-10 2013-10-23 ペーベーアードライ ビオメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗菌ペプチド
EP2030980A1 (de) * 2007-08-28 2009-03-04 AM-Pharma B.V. Lactoferrin-Mutanten
EP2050461A1 (de) 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptide basierend auf der menschlichen Lactoferrinsequenz und ihre Verwendung
EP2060586A1 (de) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB Neue synthetische Arginin-substituierte Peptide und ihre Verwendung
EP2481751A1 (de) 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Humanem Lactoferrin abgeleitete Peptide
JP6099055B2 (ja) * 2014-05-09 2017-03-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 変性病変の診断のためのリガンドとしてのフコイダン
CN107304424B (zh) * 2016-05-23 2019-05-10 成都福际生物技术有限公司 改造的转铁蛋白dna结合域、重组dna聚合酶及制备方法
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
EP3773686B1 (de) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkalische phosphatasemittel zur behandlung von bestrahlungsstörungen
CN113993541A (zh) 2019-05-06 2022-01-28 合成生物制品有限公司 基于碱性磷酸酶的肿瘤学治疗
WO2021209652A1 (es) * 2020-04-16 2021-10-21 Dermopartners,S.L. Nueva composición para ser usada en el tratamiento y la prevención de infecciones por covid-19 y otros coronavirus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2941093B2 (ja) * 1990-06-26 1999-08-25 森永乳業株式会社 ラクトフェリン分解物を有効成分とするチロシナーゼ活性阻害剤及びラクトフェリン分解物を用いる物品の処理方法
JP3173857B2 (ja) * 1991-04-24 2001-06-04 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
EP0629347B1 (de) * 1992-01-23 1997-07-02 Morinaga Milk Industry Co., Ltd. Antibakterielles mittel und behandlung von gegenständen mit diesem
JP3261175B2 (ja) * 1992-01-23 2002-02-25 森永乳業株式会社 抗菌剤とこの抗菌剤を用いて物品を処理する方法
WO1995022258A2 (en) * 1994-02-16 1995-08-24 Pharming Bv Isolation of lactoferrin from milk
JP3506274B2 (ja) * 1994-09-01 2004-03-15 雪印乳業株式会社 新規ペプチドおよび免疫賦活剤
JPH09165342A (ja) * 1995-12-14 1997-06-24 Morinaga Milk Ind Co Ltd 抗真菌剤
JPH1192375A (ja) * 1997-09-25 1999-04-06 Morinaga Milk Ind Co Ltd ニューキノロン系抗菌剤の抗菌性を増強させる抗菌剤

Also Published As

Publication number Publication date
CA2388910A1 (en) 2001-05-17
ES2256070T3 (es) 2006-07-16
CY1105008T1 (el) 2009-11-04
AU776044B2 (en) 2004-08-26
AU1901501A (en) 2001-06-06
WO2001034641A8 (en) 2002-05-10
EP1228097B1 (de) 2005-12-21
EP1228097A2 (de) 2002-08-07
DE60025026D1 (de) 2006-01-26
CA2388910C (en) 2008-10-07
DK1228097T3 (da) 2006-04-18
WO2001034641A2 (en) 2001-05-17
PT1228097E (pt) 2006-05-31
JP2003521483A (ja) 2003-07-15
DE60025026T2 (de) 2006-08-03
WO2001034641A3 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
TR200100054T2 (tr) Paroksetin metansülfonat
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
DK1095061T3 (da) Peptider baseret på sekvensen af humant lactoferring og deres anvendelse
NO20031159D0 (no) Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner
YU13301A (sh) Muskarinski agonisti i antagonisti
DE60228878D1 (de) Proteine mit il-6 inhibitorischer wirkung
SE9802937D0 (sv) Novel compounds
PT1635776E (pt) Sistemas de proteínas de transferência lipídica e sua utilização cosmética/dermatológica
TR200100637T2 (tr) Yeni doğal ürün türevleri
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
NO20020914L (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
DK1189615T3 (da) Endoparasiticid synergistisk kombination indeholdende cykliske depsipeptider og piperaziner
DE60003074D1 (de) Fusidinsäure-derivate
MXPA04006675A (es) Composicion farmaceutica que comprende glitazona y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
PL369845A1 (en) Use of 4-oxobutanoic acid derivatives in the treatment of inflammation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1228097

Country of ref document: EP